Izidor Sosič Selected Research

nitroxoline

1/2022	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
12/2020	Synthesis of Novel Nitroxoline Analogs with Potent Cathepsin B Exopeptidase Inhibitory Activity.
9/2019	Organoruthenated Nitroxoline Derivatives Impair Tumor Cell Invasion through Inhibition of Cathepsin B Activity.
1/2018	Cathepsin B inhibitors: Further exploration of the nitroxoline core.
8/2017	Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo.
8/2015	Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity.
1/2013	Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Izidor Sosič Research Topics

Disease

11	Neoplasms (Cancer) 06/2022 - 01/2013
4	Neoplasm Metastasis (Metastasis) 12/2020 - 08/2015
2	Breast Neoplasms (Breast Cancer) 04/2020 - 08/2015
2	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 08/2015
2	Fibrosarcoma 08/2017 - 08/2015
1	Lung Neoplasms (Lung Cancer) 05/2022
1	Prostatic Neoplasms (Prostate Cancer) 05/2022
1	Urinary Tract Infections (Urinary Tract Infection) 01/2022
1	COVID-19 01/2022
1	Mycoses (Diseases, Fungus) 01/2021
1	Necrosis 01/2021
1	Retinoblastoma (Glioblastoma, Retinal) 04/2020
1	Cardiotoxicity 08/2019
1	Dehydration (Water Stress) 12/2017
1	Pathologic Processes 08/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2015
1	Tuberculosis (Tuberculoses) 01/2015
1	Infections 01/2015
1	Burkitt Lymphoma (Burkitt's Lymphoma) 11/2014
1	Endometriosis 05/2012

Drug/Important Bio-Agent (IBA)

8	Cathepsin BIBA 12/2020 - 01/2013
7	nitroxolineIBA 01/2022 - 01/2013
4	Peptide Hydrolases (Proteases)FDA Link 12/2020 - 11/2016
4	LigandsIBA 04/2020 - 11/2014
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2015
3	Pharmaceutical PreparationsIBA 01/2021 - 08/2015
3	Cysteine (L-Cysteine)FDA Link 09/2019 - 11/2016
2	Proteolysis Targeting ChimeraIBA 05/2022 - 04/2020
2	Anti-Infective Agents (Microbicides)IBA 12/2020 - 08/2017
2	Biological ProductsIBA 01/2019 - 11/2014
2	CollagenIBA 01/2018 - 08/2015
1	Proto-Oncogene Proteins B-rafIBA 06/2022
1	Androgen Antagonists (Antiandrogens)IBA 05/2022
1	Androgen Receptors (Androgen Receptor)IBA 05/2022
1	AcidsIBA 03/2022
1	ixazomibIBA 03/2022
1	Bortezomib (Velcade)FDA Link 03/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	1-oxo-1H-phenalene-2,3-dicarbonitrileIBA 10/2021
1	14-alpha Demethylase InhibitorsIBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	SterolsIBA 01/2021
1	AzolesIBA 01/2021
1	ethyleneIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 04/2020
1	palbociclibIBA 04/2020
1	Baculoviral IAP Repeat-Containing 3 ProteinIBA 04/2020
1	Immunomodulating AgentsIBA 04/2020
1	Phosphotransferases (Kinase)IBA 04/2020
1	Thalidomide (Thalomid)FDA Link 04/2020
1	Retinoblastoma ProteinIBA 04/2020
1	Antineoplastic Agents (Antineoplastics)IBA 09/2019
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 08/2019
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 08/2019
1	PoisonsIBA 08/2019
1	NitrilesIBA 12/2017
1	4-cymene (p-cymene)IBA 11/2016
1	Clioquinol (Vioform)FDA Link 11/2016
1	RutheniumIBA 11/2016
1	EndopeptidasesIBA 08/2015
1	ThiadiazolesIBA 01/2015
1	Acyl Carrier ProteinIBA 01/2015
1	Oxidoreductases (Dehydrogenase)IBA 01/2015
1	Progesterone FDA LinkGeneric 05/2012
1	Dydrogesterone FDA Link 05/2012
1	Aldo-Keto ReductasesIBA 05/2012
1	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 05/2012
1	Progestins (Progestagens)IBA 05/2012

Therapy/Procedure

3	Therapeutics 01/2022 - 08/2015